{"entity":{"id":"nct01804686","kind":"trial","name":"A Long-term Extension Study of PCI-32765 (Ibrutinib)","aka":[],"tldr":"A phase 3 trial of Ibrutinib in mantle cell lymphoma and follicular lymphoma, run by Janssen Research & Development, LLC, now recruiting.","summary":"A Long-term Extension Study of PCI-32765 (Ibrutinib) is a phase 3 interventional study registered as NCT01804686 by Janssen Research & Development, LLC, with 700 participants planned, started 2013-09-09 and due to reach its primary completion in 2026-12-31. Interventions recorded: Ibrutinib. Conditions listed: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT01804686","url":"https://clinicaltrials.gov/study/NCT01804686"}],"tags":["ctgov-ingest"],"related":[],"cancers":["mantle-cell-lymphoma","follicular-lymphoma","dlbcl"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["ibrutinib"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01804686","phase":"3","setting":"PCI-32765CAN3001: A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study","sponsor":"Janssen Research & Development, LLC","participation":[{"nct":"NCT01804686","source":"https://clinicaltrials.gov/study/NCT01804686","fetchedAt":"2026-10-07T16:52:33.749Z","studySha256":"f390f2a3f2483f257a82f56e5be6d265e5d62667cae02cf7cae33b528552735a","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-10-01","leadSponsor":"Janssen Research & Development, LLC","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":539,"enrolmentType":"ACTUAL","siteCount":175,"recruitingSiteCount":0,"countries":["Argentina","Australia","Belgium","Brazil","Canada","China","Colombia","Czechia","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Japan","Mexico","Netherlands","Poland","Portugal","Puerto Rico","Russia","South Korea","Spain","Sweden","Taiwan","Turkey (Türkiye)","Ukraine","United Kingdom","United States"]}],"started":"2013-09-09","startedType":"actual","enrolled":700,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01804686/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}